Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2026-05-06 @ 5:54 AM
Study NCT ID:
NCT02573467
Status:
COMPLETED
Last Update Posted:
2018-03-13
First Post:
2015-07-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Sporadic Inclusion Body Myositis | View |